| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income (loss) | 6,327 | 3,275 | 1,315 | -1,303 |
| Depreciation expense | 280 | 190 | 97 | 286 |
| Amortization expense | 1,793 | 1,197 | 599 | 1,788 |
| Stock-based compensation expense | 664 | 434 | 209 | 613 |
| Deferred income taxes | 282 | -377 | -199 | -1,465 |
| Net (gain) loss from equity securities | 198 | -284 | -426 | -148 |
| Acquired in-process research and development expenses | 485 | 315 | 253 | 4,674 |
| In-process research and development impairments | 190 | 190 | 0 | 4,180 |
| Other, net | -213 | -124 | -91 | -294 |
| Accounts receivable, net | 546 | 213 | -79 | -67 |
| Inventories | 913 | 398 | 223 | 200 |
| Prepaid expenses and other | 275 | -93 | -12 | 113 |
| Accounts payable | -37 | -267 | -105 | 348 |
| Income tax assets and liabilities, net | -1,974 | -1,852 | -552 | -1,268 |
| Accrued and other liabilities | 401 | -410 | -244 | -197 |
| Net cash provided by operating activities | 6,692 | 2,584 | 1,757 | 7,853 |
| Purchases of marketable debt securities | 2,557 | 2,287 | 0 | 244 |
| Proceeds from sales of marketable debt securities | 514 | 295 | 0 | 2,265 |
| Proceeds from maturities of marketable debt securities | 32 | 15 | 0 | 327 |
| Acquisitions, including in-process research and development, net of cash acquired | 461 | 294 | 273 | 4,765 |
| Purchases of equity securities | 119 | 37 | 16 | 453 |
| Purchases of property, plant and equipment | 358 | 211 | 104 | 376 |
| Other investing activities, net | 9 | 13 | 23 | -23 |
| Net cash used in investing activities | -2,958 | -2,531 | -415 | -3,224 |
| Proceeds from debt financing, net of issuance costs | - | - | - | 0 |
| Proceeds from issuances of common stock | 376 | 279 | 252 | 249 |
| Repurchases of common stock under repurchase programs | 1,692 | 1,257 | 730 | 800 |
| Repayments of debt and other obligations | 1,780 | 1,771 | 1,762 | 1,963 |
| Payments of dividends | 3,009 | 2,004 | 1,010 | 2,945 |
| Other financing activities, net | -377 | -240 | -176 | -234 |
| Net cash used in financing activities | -6,482 | -4,993 | -3,426 | -5,693 |
| Effect of exchange rate changes on cash and cash equivalents | 87 | 92 | 19 | 15 |
| Net change in cash and cash equivalents | -2,661 | -4,848 | -2,065 | -1,049 |
| Cash and cash equivalents at beginning of period | 9,991 | 9,991 | 9,991 | 6,085 |
| Cash and cash equivalents at end of period | 7,330 | 5,144 | 7,926 | 5,037 |
GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD)